Treats schizophrenia. ANDA 204147, held by Avet Lifesciences. Prochlorperazine Edisylate.
As of Nov 21, 2026, ANDA 204147 (Prochlorperazine Edisylate), held by Avet Lifesciences, was first approved by FDA on Oct 15, 2013, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 15, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Prochlorperazine EdisylateEQ 5MG BASE/ML · injectable;injection | Prochlorperazine Edisylate | Rx |
| Jan 22, 2025 | Supplement 36Labeling · Standard review | Approved | None posted |
| Jun 25, 2020 | Supplement 25Labeling · Standard review | Approved | None posted |
| Sep 9, 2019 | Supplement 21Manufacturing · Standard review | Approved | None posted |
| Feb 23, 2017 | Supplement 9Labeling · Standard review | Approved | None posted |
| Oct 15, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters